The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti–…

The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to
develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on …

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma …

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that
antibodies possess several clinically relevant mechanisms of action. Many clinically useful …

Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve
durable tumor retention. This has spurred efforts to generate high affinity antibodies for use in …

We determined the extent to which additional binding energy could be achieved by diversifying
the complementarity determining regions (CDRs) located in the center of the antibody …

Whereas over 85% of human cancers are solid tumors, of the 8 monoclonal antibodies (mAbs)
currently approved for cancer therapy, 25% are directed at solid tumor surface antigens (…

Metastases from primary tumors are responsible for most cancer deaths. It has been shown
that circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with a …

Monoclonal antibodies are effective treatments for many malignant diseases. However, the
ability of antibodies to initiate tumour-antigen-specific immune responses has received less …

The use of antibodies to target tumor antigens has had limited success, partially due to the
large size of IgG molecules, difficulties in constructing smaller single chain Fv (scFv) antibody …